GUIDED THERAPEUTICS INC (GTHP)
Guided Therapeutics, Inc. is a medical technology firm specializing in the creation of medical devices. Its primary focus is on bringing to market LuViva, an innovative device designed for the non-invasive detection of cervical cancer. This technology excels at identifying both cancerous and precancerous conditions of the cervix in a painless, non-invasive manner, directly at the point of care. LuViva operates by scanning the cervix with light and subsequently analyzing both the reflected and fluorescent light emitted. Established in 1992 and headquartered in Norcross, Georgia, the company was formerly known as SpectRx, Inc. until its rebranding to Guided Therapeutics, Inc. in February 2008.
Sector: Electromedical & Electrotherapeutic Apparatus
Industry: Medical - Devices
Guided Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 96.54M shares outstanding
USGuided Therapeutics, Inc. is a medical technology firm specializing in the creation of medical devices.
Its primary focus is on bringing to market LuViva, an innovative device designed for the non-invasive detection of cervical cancer. This technology excels at identifying both cancerous and precancerous conditions of the cervix in a painless, non-invasive manner, directly at the point of care. LuViva operates by scanning the cervix with light and subsequently analyzing both the reflected and fluorescent light emitted. Established in 1992 and headquartered in Norcross, Georgia, the company was formerly known as SpectRx, Inc. until its rebranding to Guided Therapeutics, Inc. in February 2008.
Leadership
Gene S. Cartwright, Ph.D.
Chief Executive Officer, President, Acting Chief Financial Officer and Director
John E. Imhoff, M.D.
Director
Mark L. Faupel, Ph.D.
Chief Operating Officer and Director
Michael C. James
Chairman and Director
Employees
4
Country
US
Sector
Healthcare
Website
guidedinc.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Imhoff John E | Director | Conversion of Derivative | 157.4K | $11.0K | Mar 31, 2026 |
| Imhoff John E | Director | Conversion of Derivative | 157.4K | $11.0K | Mar 31, 2026 |
 Blumberg Richard P. | Director | Other | 352.0K | -- | Mar 26, 2026 |
| Imhoff John E | Director | Other | 2.2K | -- | Mar 26, 2026 |
| Imhoff John E | Director | Other | 10 | -- | Mar 26, 2026 |
| Imhoff John E | Director | Other | 40.0K | -- | Mar 26, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
 Imhoff John E Director, 10% Owner | 21.3M | 22.0% | FORM 4 |
 Blumberg Richard P. Director, 10% Owner | 10.4M | 10.8% | FORM 4 |
 Grujic Alan Director | 1.8M | 1.9% | FORM 4 |
 JAMES MICHAEL C Director | 653.5K | 0.7% | FORM 4 |
Insiders
- Imhoff John EDirector
- Blumberg Richard P.Director
- JAMES MICHAEL CDirector
- Grujic AlanDirector
based on 96.54M shares outstanding
US30d Avg
83.27K
60d Avg
53.79K
90d Avg
40.24K